Extensive Tinea Associated with Tofacitinib Therapy Masquerading as New-Onset SCLE

Rheumatoid arthritis is a chronic autoimmune disorder that often requires treatment with immunomodulatory agents. However, such interventions are not without risk of opportunistic infection. Monitoring for such conditions is critical, though recognition and treatment can prove challenging, as they may manifest atypically or masquerade as another condition entirely. We present a case of extensive tinea corporis with concomitant tinea capitis masquerading as new-onset SCLE in a patient being treated for rheumatoid arthritis with the Janus kinase inhibitor tofacitinib.